Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03644563 | Men and Women Offering Understanding of Throat HPV(MOUTH) | active not recruiting | — | 1,500 | Johns Hopkins UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06991738 | 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer | not yet recruiting | Phase 1 / Phase 2 | 18 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04216732 | Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management | recruiting | — | 2,030 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | recruiting | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06980038 | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07124000 | DESTINY-PANTUMOUR04(DP-04) | recruiting | — | 100 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07142005 | Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer | recruiting | — | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07195734 | Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | recruiting | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02293954 | Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05575440 | Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer | terminated | — | 11 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06475989 | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | recruiting | Phase 3 | 264 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04339478 | Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection(FLUOBCC) | completed | — | 180 | Aristotle University Of ThessalonikiOTHER | 2 | Sep 23, 2026 | clinicaltrials |
| NCT05290194 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05814549 | A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) | active not recruiting | — | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06305676 | Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)(BASH OPC) | recruiting | — | 400 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT01660984 | Natural History Study of Children and Adults With Medullary Thyroid Cancer | active not recruiting | — | 105 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03765333 | GETNE Registration of Thyroid Cancer | recruiting | — | 20 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04522570 | Thermal Ablation of Cervical Metastases From Thyroid Carcinoma | completed | N/A | 84 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04671667 | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04708470 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05172245 | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | recruiting | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07006727 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | recruiting | Phase 1 | 116 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 22, 2026 | clinicaltrials |
| NCT07060261 | Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma | recruiting | N/A | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07428057 | Postoperative Hypocalcemia After Thyroidectomy | recruiting | — | 600 | Minia UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07565740 | Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05172258 | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | suspended | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT07832266 | Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) | not yet recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT00498875 | Depression and Adherence in Head and Neck Cancer | active not recruiting | — | 185 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06507878 | Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.(GRASSROOT) | recruiting | — | 459 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04040673 | RAman For Thyroid cancER(RAFTER) | withdrawn | — | 0 | Gloucestershire Hospitals NHS Foundation TrustOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04544111 | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | active not recruiting | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05798780 | The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors | completed | N/A | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06629597 | A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) | active not recruiting | Phase 3 | 400 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07177443 | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 710 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824856 | Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04467021 | Cancer and Blood Pressure Management, CARISMA Study | active not recruiting | N/A | 61 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06029270 | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | recruiting | Phase 2 | 156 | National Cancer Institute (NCI)NIH | 5 | Sep 16, 2026 | clinicaltrials |
| NCT06235216 | Sacituzumab govitEcan in THYroid Cancers(SETHY) | recruiting | Phase 2 | 42 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07140757 | Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers | recruiting | — | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07797881 | A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 60 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823439 | Pattern and Surgical Outcome of Papillary Thyroid Cancer at Sohag University Hospitals | not yet recruiting | — | 30 | Sohag UniversityOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07823543 | Educational Videos for Thyroid Surgery Patient | not yet recruiting | N/A | 400 | West China HospitalOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT04104529 | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department(BCB RIV) | recruiting | N/A | 350 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials